Free Trial

Cardlytics (CDLX) Stock Price, News & Analysis

+0.29 (+3.09%)
(As of 03:16 PM ET)
Today's Range
50-Day Range
52-Week Range
471,687 shs
Average Volume
1.49 million shs
Market Capitalization
$472.68 million
P/E Ratio
Dividend Yield
Price Target

Cardlytics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
32.3% Upside
$12.75 Price Target
Short Interest
11.48% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.94mentions of Cardlytics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$10.96 M Bought Last Quarter
Proj. Earnings Growth

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.85 out of 5 stars

Business Services Sector

74th out of 313 stocks

Computer Programming, Data Processing, & Other Computer Related Industry

15th out of 59 stocks

CDLX stock logo

About Cardlytics Stock (NASDAQ:CDLX)

Cardlytics, Inc. operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing. The company was incorporated in 2008 and is headquartered in Atlanta, Georgia.

CDLX Stock Price History

CDLX Stock News Headlines

5 Best Marketing Stocks to Buy
Why Is Cardlytics (CDLX) Stock Down 29% Today?
Cardlytics: Q1 Earnings Snapshot
CDLX Jul 2024 9.000 put (CDLX240719P00009000)
Cardlytics executive sells over $3.5k in stock
Cardlytics, Inc. (CDLX)
The Analyst Verdict: Cardlytics In The Eyes Of 5 Experts
Craig-Hallum Reaffirms Their Buy Rating on Cardlytics (CDLX)
See More Headlines
Receive CDLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardlytics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Computer programming, data processing, & other computer related
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$309.20 million
Cash Flow
$1.30 per share
Book Value
$3.43 per share


Free Float
Market Cap
$473.65 million

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Mr. Karim Temsamani (Age 50)
    CEO & Director
    Comp: $917.94k
  • Ms. Alexis DeSieno (Age 40)
    Chief Financial Officer
    Comp: $565.84k
  • Mr. Amit Gupta (Age 51)
    COO & GM of Bridg
    Comp: $732.48k
  • Mr. Nick Lynton (Age 41)
    Chief Legal & Privacy Officer and Secretary
    Comp: $577.42k
  • Mr. Peter Chan
    Chief Technology Officer
  • Mr. Peter Davies
    Head of Sales Strategy & Operations
  • Ms. Carson Napps
    Head of People
  • Mr. Jose Singer
    Chief Product Officer
  • Ms. Evelyne Forester
    Chief Business Officer

CDLX Stock Analysis - Frequently Asked Questions

Should I buy or sell Cardlytics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cardlytics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CDLX shares.
View CDLX analyst ratings
or view top-rated stocks.

What is Cardlytics' stock price target for 2024?

4 Wall Street analysts have issued twelve-month price objectives for Cardlytics' stock. Their CDLX share price targets range from $9.00 to $18.00. On average, they expect the company's stock price to reach $12.75 in the next year. This suggests a possible upside of 32.3% from the stock's current price.
View analysts price targets for CDLX
or view top-rated stocks among Wall Street analysts.

How have CDLX shares performed in 2024?

Cardlytics' stock was trading at $9.21 on January 1st, 2024. Since then, CDLX shares have increased by 4.7% and is now trading at $9.64.
View the best growth stocks for 2024 here

When is Cardlytics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 6th 2024.
View our CDLX earnings forecast

How were Cardlytics' earnings last quarter?

Cardlytics, Inc. (NASDAQ:CDLX) issued its quarterly earnings results on Thursday, March, 14th. The company reported ($0.14) earnings per share (EPS) for the quarter. The company earned $89.17 million during the quarter. Cardlytics had a negative net margin of 55.23% and a negative trailing twelve-month return on equity of 25.36%.

What ETF holds Cardlytics' stock?

Invesco Dorsey Wright Technology Momentum ETF holds 382,812 shares of CDLX stock, representing 0.90% of its portfolio.

What guidance has Cardlytics issued on next quarter's earnings?

Cardlytics issued an update on its second quarter 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $73.0 million-$81.0 million, compared to the consensus revenue estimate of $81.4 million.

What is Lynne Laube's approval rating as Cardlytics' CEO?

26 employees have rated Cardlytics Chief Executive Officer Lynne Laube on Lynne Laube has an approval rating of 86% among the company's employees. 61.0% of employees surveyed would recommend working at Cardlytics to a friend.

What other stocks do shareholders of Cardlytics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardlytics investors own include NVIDIA (NVDA), Block (SQ), DocuSign (DOCU), Advanced Micro Devices (AMD), Caterpillar (CAT), Walt Disney (DIS), Alibaba Group (BABA), Trade Desk (TTD), QUALCOMM (QCOM) and Twilio (TWLO).

When did Cardlytics IPO?

Cardlytics (CDLX) raised $76 million in an initial public offering on Friday, February 9th 2018. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. BofA Merrill Lynch and J.P. Morgan acted as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey, Raymond James and KeyBanc Capital Markets were co-managers.

Who are Cardlytics' major shareholders?

Cardlytics' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.59%), Baillie Gifford & Co. (1.95%), Kent Lake Capital LLC (0.51%), Jacobs Levy Equity Management Inc. (0.46%), Simplex Trading LLC (0.00%) and Perbak Capital Partners LLP (0.33%). Insiders that own company stock include Amit Gupta, Andrew Christiansen, Clifford Sosin, John V Balen, John V Balen, Karim Saad Temsamani, Kirk Somers, Lynne Marie Laube, Nicholas Hollmeyer Lynton, S Aimee Lapic, Scott D Grimes and Scott D Grimes.
View institutional ownership trends

How do I buy shares of Cardlytics?

Shares of CDLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Cardlytics have any subsidiaries?
The following companies are subsidiares of Cardlytics: Bridg, Cardlytics Services India Private Limited, Cardlytics UK Limited, and DOSH.
Read More
This page (NASDAQ:CDLX) was last updated on 5/28/2024 by Staff

From Our Partners